"For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction"@en . . . . . "Tissue-type plasminogen activator precursor"@en . " "@en . "tPA"@en . . "Humans and other mammals"@en . . . . . "133652-38-7"@en . . . . . . "Reteplase"@en . . . . . . "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. "@en . . . . . . "t-plasminogen activator"@en . "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF)."@en . "t- PA"@en . "approved"@en .